NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $29.81 -0.18 (-0.60%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Stoke Therapeutics Stock (NASDAQ:STOK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Stoke Therapeutics alerts:Sign Up Key Stats Today's Range$29.15▼$30.0350-Day Range$27.68▼$33.4652-Week Range$19.55▼$40.22Volume714,010 shsAverage Volume846,612 shsMarket Capitalization$1.92 billionP/E RatioN/ADividend YieldN/APrice Target$44.25Consensus RatingModerate Buy Company Overview Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins. The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy. In addition to STK-001, Stoke is advancing STK-002, its preclinical candidate for spinocerebellar ataxia type 6 (SCA6), along with other discovery-stage programs targeting genetic diseases characterized by insufficient protein levels. Stoke’s approach aims to address the underlying genetic deficiency rather than solely treating symptoms, positioning its pipeline to potentially benefit a range of patient populations with high unmet medical needs. Since going public on the Nasdaq exchange in early 2020, Stoke Therapeutics has grown its research capabilities and established strategic collaborations to support its development efforts. The company’s leadership team brings together expertise in molecular biology, neurology and clinical development, guiding Stoke’s mission to translate its TANGO platform into transformative therapies. Stoke serves patient communities and clinical partners globally, with ongoing and planned trials conducted across North America and Europe.AI Generated. May Contain Errors. Read More Stoke Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreSTOK MarketRank™: Stoke Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 264th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialStoke Therapeutics has a consensus price target of $44.25, representing about 48.4% upside from its current price of $29.81.Amount of Analyst CoverageStoke Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Stoke Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Stoke Therapeutics are expected to grow in the coming year, from ($3.52) to ($3.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -8.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -8.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 5.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.25% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 17.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.95 News SentimentStoke Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.MarketBeat FollowsOnly 1 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,068,939.00 in company stock.Percentage Held by Insiders9.60% of the stock of Stoke Therapeutics is held by insiders.Percentage Held by InstitutionsStoke Therapeutics has minimal institutional ownership at this time.Read more about Stoke Therapeutics' insider trading history. Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STOK Stock News HeadlinesStoke Therapeutics (NASDAQ:STOK) Insider Sells 5,545 Shares of StockSeptember 4 at 6:52 AM | insidertrades.comStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of ...September 3 at 8:02 PM | markets.businessinsider.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 5 at 1:00 AM | Banyan Hill Publishing (Ad)Stoke Therapeutics Inc 0GTSeptember 1, 2026 | morningstar.comMStoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congressSeptember 1, 2026 | msn.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 29, 2026 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,861 SharesAugust 19, 2026 | insidertrades.comBarry Ticho Sells 7,176 Shares of Stoke Therapeutics (NASDAQ:STOK) StockAugust 6, 2026 | insidertrades.comSee More Headlines STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $31.74 at the start of the year. Since then, STOK stock has decreased by 6.1% and is now trading at $29.81. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its earnings results on Monday, August, 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by $0.14. The company had revenue of $9.33 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 59.36% and a negative net margin of 753.60%. Read the conference call transcript. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $118 million in an initial public offering on Wednesday, June 19th 2019. The company issued 7,891,110 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Top institutional shareholders of Stoke Therapeutics include BlackRock Inc. (9.11%), Wellington Management Group LLP (5.45%), Jupiter Topco LLC (2.81%) and California State Teachers Retirement System (2.54%). Insiders that own company stock include Skorpios Trust, Adrian R Krainer, Edward M Md Kaye, Arthur Tzianabos, Jonathan Allan, Stephen J Tulipano, Barry Ticho, Jason Hoitt, Thomas Leggett and Arthur A Levin. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Compass Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings8/03/2026Today9/05/202612th Annual Cantor Fitzgerald Global Healthcare Conference9/09/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 STOK's financial health is in the Green zone, according to TradeSmith. STOK has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:STOK CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year Founded2014Price Target and Rating Average Price Target for Stoke Therapeutics$44.25 High Price Target$60.00 Low Price Target$35.00 Potential Upside/Downside+48.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.89 million Net Margins-753.60% Pretax Margin-758.23% Return on Equity-59.36% Return on Assets-51.46% Debt Debt-to-Equity RatioN/A Current Ratio7.69 Quick Ratio7.69 Sales & Book Value Annual Sales$27.59 million Price / Sales69.72 Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book5.56Miscellaneous Outstanding Shares64,526,000Free Float58,332,000Market Cap$1.92 billion OptionableOptionable Beta1.23 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:STOK) was last updated on 9/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
